{
    "nctId": "NCT01140776",
    "briefTitle": "Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy",
    "officialTitle": "OSNA Neoadjuvant Feasibility Study in Breast Cancer Patients",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Neoplasms, Breast Diseases",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Prospectively assess the performance of the OSNA Breast Cancer System for the detection of SLN metastasis in subjects treated with neoadjuvant therapy prior to SLN biopsy by comparing results with standard histopathology evaluation.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female\n* 18 years of age or older\n* Diagnosed pre-surgically with T1-T3 or T4 non-inflammatory breast cancer, clinically node positive or node negative upon clinical examination\n* Scheduled for SLN biopsy after receiving neoadjuvant hormonal or chemotherapy\n* Subjects (or the subjects' legal representatives) who have read, understood (to the best of their ability) and signed the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant subjects, confirmed by interview with either subject or treating physician\n* Subjects previously diagnosed with other invasive cancer. Subjects with skin cancer (basal cell and squamous cell carcinoma) may be included, except for subjects diagnosed with melanoma\n* Participation in other neoadjuvant protocols specifically requiring SLN biopsy prior to administration of neoadjuvant chemotherapy or hormonal therapy\n* Subjects who have been judged to be an inappropriate candidate by any medical care provider (e.g., surgeon, oncologist or pathologist).",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}